Taysha Gene Therapies, Inc. (TSHA) stock analysis

TSHA · Taysha Gene Therapies, Inc.

Latest recorded price: USD 4.00

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth 57.5%, free cash flow margin -960.1%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare